Pharmacokinetics and Safety Profiles of DA-1229_01 in Healthy Subjects at Fasting State

An Open Label, Randomized, Single Dose, 2-sequence, 2-period, Cross-over Study to Evaluate the Pharmacokinetics and Safety of DA-1229_01 in Healthy Subjects at Fasting State

This clinical study is to evaluate the safety/tolerability and pharmacokinetics of DA-1229_01 at fasting state.

Inclusion Criteria:

• Healthy volunteers
• BMI between 18 and 30 kg/m2
• Body weight: Male ≥ 50kg, Female ≥ 45kg
• Subjects who have signed an informed consent themselves after receiving detailed explanation about clinical study

Exclusion Criteria:

• Subjects with clinically significant medical history
• Subjects with history of drug abuse or addicted
• Subjects with allergy or drug hypersensitivity